In GC patients, the combined HR from 4 studies was 1.88 (455 patients, 95% CI 1.44–2.46, p < 0.00001), which indicated that the overexpression of SATB1 increase mortality by 1.88 fold (Figure 6B). Here, SATB1 is linked to gastric cancer.